StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences acquired in-process research and development (IPR&D) expenses ($M) ($M)

Form 10-Q / 10-K Consolidated Statements of Operations

QuarterlyAnnual
Latest, Q2 2026
11,183
Period ended Jun 30, 2026
Change on a year earlier
+18,232.8%
61 in Q2 2025
History
29 quarters
Since Q2 2019
Sources
20
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAcquired in-process research and development (IPR&D) expenses ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202611,183+18,232.8%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026107-57.7%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 2025539-5,000.0%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 2025170-66.3%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202561+60.5%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025253-93.9%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 2024-11-103.2%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2024Sep 30, 2024505+454.9%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202438-83.9%Form 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 20244,131+758.8%Form 8-K (exhibit991earningspressrel.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 2023347+119.6%Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2023Sep 30, 202391-79.7%Form 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 2023236-28.5%Form 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 2023481+5,912.5%Form 10-Q (filed 2023-05-03) ↗
Q4 2022Dec 31, 2022158-76.4%Form 10-K (filed 2023-02-22) ↗
Q3 2022Sep 30, 2022448+589.2%Form 10-Q (filed 2022-11-02) ↗

Breakdown

What makes up acquired in-process research and development (ipr&d) expenses ($m)

Cite this data

StockData. (2026). Gilead Sciences Acquired in-process research and development (IPR&D) expenses ($M) ($M), quarterly Q2 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/iprd_acquired_exp

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.